查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433434

2023-2030年全球涂药支架市场

Global Drug-Eluting Stent Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 105 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期（2023-2030年），全球药物洗脱支架市场将以7.6%的CAGR成长。市场成长的一些主要因素包括老年人口的增加、心血管疾病（週边和冠状动脉疾病）盛行率的增加、有利的政府倡议和政策以及新型和增强型技术产品的推出。美国心臟协会（AHA）发表了一篇题为「週边动脉疾病的健康差异」的文章：AHA 的科学声明，根据该文章，週边动脉疾病（PAD）影响着全球 2 亿人。在美国，某些人口群体的 PAD 盛行率和临床效果要高得多。 PAD 的社会和临床影响包括个别残疾、忧郁、小截肢和大截肢以及心臟和脑血管事件的发生率较高。

细分市场前景

全球药物洗脱支架市场按材料、产品、类型、应用和最终用户细分。根据材料，市场细分为不銹钢、钴铬合金等。其他还有铂铬合金。根据类型，市场分为永久性和可生物降解。根据应用，市场分为冠状动脉支架和周边动脉支架。此外，根据最终用户，市场细分为医院和心导管实验室。在最终用户中，由于成本较低、效率较高和可用性较高，预计医院细分市场在预测期内将占据最大的市场份额。

预计冠状动脉支架细分市场将在全球涂药支架市场中占据相当大的份额

在这些应用中，冠状动脉支架植入术预计将在预测期内成长。细分市场的成长归因于冠状动脉疾病（CAD）发病率的增加、技术进步和有凝聚力的政府政策。在所有CVD中，CAD的盛行率最高。英国心臟基金会（BHF）2023年1月公布的资料报告称，2021年最常见的心血管疾病是冠心病（缺血性）心臟病（2019年全球患病率估计为2亿）、外周动脉（血管）疾病（1.1亿） 、中风（1亿）和心房颤动（6000万）。此外，报告也显示，北美心臟病和循环系统疾病盛行率为 4,800 万人，欧洲为 1 亿，非洲和中东为 9,800 万人，拉丁美洲为 4,800 万人，亚洲和中东地区为 4,800 万人。澳洲为3.4亿。

区域展望

全球药物洗脱支架市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国） 、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于老年人口的增加、冠状动脉疾病的盛行率增加以及医疗保健支出的增加，预计欧洲将在预测期内成长，从而推动欧洲的药物洗脱支架市场。

北美地区预计全球药物洗脱支架市场复合CAGR显着成长

预计在预测期内，北美将在药物洗脱支架市场中占据显着份额。随着老年人口的不断增加，动脉疾病的发生率也随之增加，需要更有效的治疗解决方案，例如药物洗脱支架。由于久坐的生活方式和不良的饮食选择，以动脉斑块增加为标誌的动脉粥状硬化盛行率也急剧上升。根据美国国立卫生研究院（NIH）发布的研究报告，2020年3月，美国成年人动脉粥状硬化性心血管疾病（ASCVD）盛行率为1830万（8.0%）。这种情况会显着导致各种心血管疾病，包括心臟病发作和中风。为了应对这种日益严重的健康问题，医疗专业人员越来越多地转向药物洗脱支架作为动脉粥状硬化的首选治疗方法。根据美国心臟协会的数据，2020 年，在美国，冠状动脉心臟病 (CHD) 是美国 CVD 死亡的主要原因 (41.2%)，其次是中风 (17.3%)、其他 CVD (16.8%) 、高血压（12.9% ）和心臟衰竭（9.2%）。美国成年人中动脉粥状硬化性心血管疾病 (ASCVD) 的盛行率为 1,830 万人 (8.0%)。去年有 690,524 名成年人患有急性冠状动脉综合征，其中超过 600 万人处于极高风险。

市场参与者展望

服务药物洗脱支架市场的主要公司包括 Abbott Laboratories、Boston Scientific Corp.、Biotronik SE & Co. KG、Medtronic Plc、Terumo Corp. 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 5 月，CoSo Health 与 Medinol 签署了新一代细支柱药物洗脱支架 (DES) EluNIR (TM) 在美国的经销协议。 Medinol 是植入式医疗设备开发的先驱。

报告涵盖：

  • 2023年市场价值资料分析及2031年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球药物洗脱支架市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Abbott Laboratories
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Boston Scientific Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Biotronik SE & Co. KG
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Medtronic Plc
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Terumo Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 全球涂药支架市场（依材料）
    • 不銹钢
    • 钴铬合金
    • 其他（铂铬合金）
  • 按类型分類的全球涂药支架市场
    • 永恆的
    • 可生物降解
  • 全球涂药支架市场（依应用）
    • 冠状动脉支架置放术
    • 週边动脉支架置入术
  • 按最终用户分類的全球药物洗脱支架市场
    • 医院
    • 心导管实验室

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Alvimedica SA
  • B. Braun SE
  • Biosensors International Group, Ltd.
  • Cardionovum GmbH
  • Cook Group Inc.
  • Elixir Medical Corp.
  • Hexacath
  • InspireMD Inc.
  • JW Medical Systems LTD.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • MicroPort Scientific Corp.,
  • OrbusNeich Medical Co. Group Holdings Ltd.
  • Sino Medical Sciences Technology Inc.
  • Translumina GmbH
  • Vascular Concepts Ltd.
Product Code: OMR2028102

Global Drug-eluting Stent Market Size, Share & Trends Analysis Report by material (Stainless Steel, Cobalt-Chromium Alloy, and Others), By Type, (Permanent and Biodegradable), By Application (Coronary Artery Stenting and Peripheral Artery Stenting), and by End-User (Hospitals and Cardiac Catheterization Laboratories), Forecast Period (2024-2031)

The global drug-eluting stent market is anticipated to grow at a CAGR of 7.6% during the forecast period (2023-2030). Some of the major factors attributed to the market growth include the rising geriatric population, increasing prevalence of cardiovascular diseases (peripheral and coronary artery diseases), favorable government initiatives and policies, and the introduction of new and enhanced technological products. The American Heart Association (AHA) published an article called "Health Disparities in Peripheral Artery Disease": A Scientific Statement from the AHA, according to which peripheral artery disease (PAD) affects 200 million individuals globally. In the US, certain demographic groups experience a disproportionately higher prevalence and clinical effect of PAD. The social and clinical effect of PAD includes higher rates of individual disability, depression, minor and major limb amputation along with cardiovascular and cerebrovascular events.

Segmental Outlook

The global drug-eluting stent market is segmented by material, product, type, application, and end-users. Based on the material, the market is sub-segmented into stainless steel, cobalt-chromium alloy, and others. Others include platinum-chromium alloy. Based on the type, the market is sub-segmented into permanent, and biodegradable. Based on the application, the market is divided into coronary artery stenting and peripheral artery stenting. Further, based on end-users, the market is sub-segmented into hospitals and cardiac catheterization laboratories. Among the end-users, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period, owing to the lower costs, higher efficiency, and availability.

The Coronary Artery Stenting Sub-Segment is Anticipated to Hold a Considerable Share of the Global Drug-Eluting Stent Market

Among the applications, the coronary artery stenting sub-segment is expected to grow over the forecast period. Segmental growth is attributed to the increasing incidence of coronary artery diseases (CAD), technological advancements, and cohesive government policies. Among all CVDs, CAD has the highest prevalence. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions are coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases in North America was 48 million, in Europe it was 100 million, in Africa and the Middle East it was 98 million, in Latin America it was 48 million, and in Asia and Australia it was 340 million.

Regional Outlook

The global drug-eluting stent market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to grow over the forecast period, owing to the increasing geriatric population, increasing prevalence of coronary artery diseases the rising healthcare expenditure, driving the drug-eluting stent market in Europe.

The North American region is Expected to Grow at a Significant CAGR in the Global Drug-eluting Stent Market

North America is expected to hold a prominent share in the Drug-eluting Stent market during the forecast period. With the rising elderly population, there is an increased inclination to arterial diseases, requiring more effective treatment solutions such as drug-eluting stents. The prevalence of atherosclerosis, marked by the increase of plaque in arteries, has also surged owing to sedentary lifestyles and poor dietary choices. According to research reports published by the National Institutes of Health (NIH), in March 2020, the prevalence of atherosclerotic cardiovascular disease (ASCVD) among adults in the US is 18.3 million (8.0%). This condition significantly contributes to various cardiovascular diseases, including heart attacks and strokes. In response to this mounting health concern, medical professionals are increasingly turning to drug-eluting stents as a preferred treatment for atherosclerosis. According to the American Heart Association, in 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), and heart failure (9.2%). The prevalence of atherosclerotic cardiovascular disease (ASCVD) amongst adults in the US is 18.3 million (8.0%). 690,524 adults had an acute coronary syndrome event last year, and over 6 million are at very high risk.

Market Players Outlook

The major companies serving the drug-eluting stent market include Abbott Laboratories, Boston Scientific Corp., Biotronik SE & Co. KG, Medtronic Plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, CoSo Health signed a US distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES). Medinol is a pioneer in the development of implantable medical devices.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global drug-eluting stent market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Boston Scientific Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Biotronik SE & Co. KG
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Medtronic Plc
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Terumo Corp.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Drug-Eluting Stent Market by Material
    • 4.1.1. Stainless Steel
    • 4.1.2. Cobalt-Chromium Alloy
    • 4.1.3. Others (Platinum-Chromium Alloy)
  • 4.2. Global Drug-Eluting Stent Market by Type
    • 4.2.1. Permanent
    • 4.2.2. Biodegradable
  • 4.3. Global Drug-Eluting Stent Market by Application
    • 4.3.1. Coronary Artery Stenting
    • 4.3.2. Peripheral Artery Stenting
  • 4.4. Global Drug-eluting Stent Market by End-User
    • 4.4.1. Hospitals
    • 4.4.2. Cardiac Catheterization Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alvimedica SA
  • 6.2. B. Braun SE
  • 6.3. Biosensors International Group, Ltd.
  • 6.4. Cardionovum GmbH
  • 6.5. Cook Group Inc.
  • 6.6. Elixir Medical Corp.
  • 6.7. Hexacath
  • 6.8. InspireMD Inc.
  • 6.9. JW Medical Systems LTD.
  • 6.10. Lepu Medical Technology (Beijing) Co., Ltd.
  • 6.11. MicroPort Scientific Corp.,
  • 6.12. OrbusNeich Medical Co. Group Holdings Ltd.
  • 6.13. Sino Medical Sciences Technology Inc.
  • 6.14. Translumina GmbH
  • 6.15. Vascular Concepts Ltd.

LIST OF TABLES

  • 1. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 2. GLOBAL DRUG-ELUTING STENT OF STAINLESS-STEEL MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3. GLOBAL DRUG-ELUTING STENT OF COBALT-CHROMIUM ALLOY MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4. GLOBAL DRUG-ELUTING STENT OF OTHER MATERIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 5. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 6. GLOBAL PERMANENT DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7. GLOBAL BIODEGRADABLE DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 8. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 9. GLOBAL DRUG-ELUTING STENT FOR CORONARY ARTERY STENTING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 10. GLOBAL DRUG-ELUTING STENT FOR PERIPHERAL ARTERY STENTING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 12. GLOBAL DRUG-ELUTING STENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. GLOBAL DRUG-ELUTING STENT FOR CARDIAC CATHETERIZATION LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 16. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 17. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 18. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 19. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 20. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 21. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 22. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 23. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 24. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 25. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 26. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 27. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 28. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 29. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 30. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 31. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 32. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 33. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 34. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY MATERIAL, 2023 VS 2031 (%)
  • 2. GLOBAL DRUG-ELUTING STENT OF STAINLESS-STEEL MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 3. GLOBAL DRUG-ELUTING STENT OF COBALT-CHROMIUM ALLOY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 4. GLOBAL DRUG-ELUTING STENT OF OTHER MATERIALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 5. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY TYPE, 2023 VS 2031 (%)
  • 6. GLOBAL PERMANENT DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 7. GLOBAL BIODEGRADABLE DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 8. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
  • 9. GLOBAL DRUG-ELUTING STENT FOR CORONARY ARTERY STENTING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 10. GLOBAL DRUG-ELUTING STENT FOR PERIPHERAL ARTERY STENTING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 11. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023 VS 2031 (%)
  • 12. GLOBAL DRUG-ELUTING STENT FOR HOSPITALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 13. GLOBAL DRUG-ELUTING STENT FOR CARDIAC CATHETERIZATION LABORATORIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 14. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 15. US DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 16. CANADA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. UK DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. FRANCE DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. GERMANY DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. ITALY DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. SPAIN DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. REST OF EUROPE DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. INDIA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. CHINA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. JAPAN DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. SOUTH KOREA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 28. REST OF THE WORLD DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)